A Phase I, Clinical Study to Evaluate Safety and Immunogenicity of the Ii-Key Vaccine

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 28 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jun 2021 According to a NuGenerex Immuno-Oncology media release, stability studies are ongoing to support the IND, which is currently being compiled for submission to FDA.
25 Feb 2021 According to a Generex Biotechnology Corporation media release, company plan to submit the IND to the FDA as soon as the GMP production of the Ii-Key vaccine is completed in the coming weeks.
31 Dec 2020 According to a Generex Biotechnology Corporation media release, an IND is being prepared for FDA submission in early 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com